The estimated Net Worth of Robert Berman is at least $17.1 Million dollars as of 8 July 2020. Mr. Berman owns over 58,404 units of Biohaven Ltd stock worth over $2,098,371 and over the last 8 years he sold BHVN stock worth over $14,492,780. In addition, he makes $521,060 as Lead - Special Projects and Medical Oversight at Biohaven Ltd.
Sign up
Mr. Berman BHVN stock SEC Form 4 insiders trading
Robert has made over 17 trades of the Biohaven Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 58,404 units of BHVN stock worth $35,626 on 8 July 2020.
The largest trade he's ever made was selling 160,000 units of Biohaven Ltd stock on 9 November 2017 worth over $4,121,600. On average, Robert trades about 39,641 units every 61 days since 2017. As of 8 July 2020 he still owns at least 58,745 units of Biohaven Ltd stock.
You can see the complete history of Mr. Berman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Berman biography
Robert Berman M.D. serves as Lead - Special Projects and Medical Oversight of the Company. Prior to this, from November 2015 to August 2019, he served as chief medical officer. From December 2013 to November 2015, he served as president of Biohaven Medical Services LLC and, prior to that, served as a group director of global clinical research at BMS from September 2003 to November 2013. Prior to his time at BMS, Dr. Berman was an associate director of clinical sciences, early development at Pfizer from November 2000 to September 2003. Since October 2012, Dr. Berman has also continued to serve as an adjunct professor of psychiatry at Yale University School of Medicine. Dr. Berman received his B.A. in molecular biophysics and biochemistry from Yale University and his M.D. from Mount Sinai School of Medicine of New York University.
What is the salary of Robert Berman?
As the Lead - Special Projects and Medical Oversight of Biohaven Ltd, the total compensation of Robert Berman at Biohaven Ltd is $521,060. There are 14 executives at Biohaven Ltd getting paid more, with Vlad Coric having the highest compensation of $6,787,630.
How old is Robert Berman?
Robert Berman is 57, he's been the Lead - Special Projects and Medical Oversight of Biohaven Ltd since 2019. There are 6 older and 8 younger executives at Biohaven Ltd. The oldest executive at Biohaven Ltd is Julia Gregory, 67, who is the Independent Director.
What's Robert Berman's mailing address?
Robert's mailing address filed with the SEC is C/O BIOHAVEN PHARMACEUTICALS, INC., 215 CHURCH STREET, NEW HAVEN, CT, 06510.
Insiders trading at Biohaven Ltd
Over the last 8 years, insiders at Biohaven Ltd have traded over $8,186,598,135 worth of Biohaven Ltd stock and bought 8,852,002 units worth $137,738,037 . The most active insiders traders include Robert J Hugin, John W Childs und Declan Doogan. On average, Biohaven Ltd executives and independent directors trade stock every 14 days with the average trade being worth of $2,840,776. The most recent stock trade was executed by John W Childs on 18 July 2024, trading 28,400 units of BHVN stock currently worth $1,013,028.
What does Biohaven Ltd's logo look like?
Complete history of Mr. Berman stock trades at Biohaven Ltd
Biohaven Ltd executives and stock owners
Biohaven Ltd executives and other stock owners filed with the SEC include:
-
Vlad Coric,
Chief Executive Officer, Director -
William Jones,
Chief Commercial Officer, Migraine and Common Diseases -
Charles Conway,
Chief Scientific Officer -
Kimberly Gentile,
Senior Vice President - Clinical Operations -
James Engelhart,
Chief Financial Officer, Treasurer -
Elyse Stock,
Chief Medical Officer -
John Tilton,
Chief Commercial Officer, Rare and Orphan Diseases -
Dr. Vladimir Coric M.D.,
Chairman, CEO & Pres -
William Jones M.B.A.,
Chief Commercial Officer of Migraine & Common Diseases -
Julia Gregory,
Independent Director -
John Childs,
Director -
Gregory Bailey,
Director -
Dr. Elyse Stock M.D.,
Chief Medical Officer -
Kimberly Gentile,
Sr. VP of Clinical Operations -
Robert Berman,
Lead - Special Projects and Medical Oversight -
Robert Hugin,
Director -
Michael Heffernan,
Director -
Thomas Lynch,
Chairman of the Board -
Clifford Bechtold M.S.,
Pres & GM of Biohaven Ireland and Chief Compliance Officer -
Wendy Goss,
Exec. Admin. Assistant -
Dr. Charles Conway,
Chief Scientific Officer -
George C. Clark,
VP & Chief Accounting Officer -
Matthew DeLawder,
Director of Accounting -
Matthew Buten,
Chief Financial Officer -
Albert Cha,
Director -
Robert Repella,
Director -
Eric Aguiar,
-
Biotech Inc. Portage,
-
Declan Doogan,
-
Irina Antonijevic,
-
Kishan Mehta,
-
George C. Clark,
VP, Chief Accounting Officer -
Matthew Buten,
Chief Financial Officer -
Pharmaceutical Holding Co L...,
-
Bruce Car,
Chief Scientific Officer